Literature DB >> 21516379

Valproate-induced Fanconi syndrome in a 27-year-old woman.

Sandeep M Patel1, Jonathan Graff-Radford, Mark L Wieland.   

Abstract

Valproate-induced Fanconi Syndrome (VFS) is a rare complication of this therapy that has been previously described only in children with epilepsy. We report the first known case of an adult with VFS. Metabolic derangements lead patients to present with fatigue, confusion, weakness, and even bone fractures. Identification and discontinuation of the offending agent is the treatment of choice and helps confirm the diagnosis. This case highlights the importance of surveillance for metabolic derangements among patients on long term therapy with this commonly prescribed medication.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21516379      PMCID: PMC3157517          DOI: 10.1007/s11606-011-1708-7

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  18 in total

1.  Valproate-induced proximal renal tubular dysfunction: clinically relevant in the severely disabled epileptic population.

Authors:  Stephen L Jaffe; Martha Sanford
Journal:  Epilepsia       Date:  2005-04       Impact factor: 5.864

2.  Reversible Fanconi syndrome associated with valproate therapy.

Authors:  M B Lande; M S Kim; C Bartlett; L M Guay-Woodford
Journal:  J Pediatr       Date:  1993-08       Impact factor: 4.406

3.  Anticonvulsants as a cause of Fanconi syndrome.

Authors:  G C Smith; J W Balfe; S W Kooh
Journal:  Nephrol Dial Transplant       Date:  1995       Impact factor: 5.992

4.  Secondary renal Fanconi syndrome caused by valproate therapy.

Authors:  Toru Watanabe; Hideto Yoshikawa; Sawako Yamazaki; Yuki Abe; Tokinari Abe
Journal:  Pediatr Nephrol       Date:  2005-03-23       Impact factor: 3.714

Review 5.  Carnitine: an overview of its role in preventive medicine.

Authors:  B S Kendler
Journal:  Prev Med       Date:  1986-07       Impact factor: 4.018

6.  Renal toxicity induced by valproic acid (Depakene).

Authors:  E Hawkins; E Brewer
Journal:  Pediatr Pathol       Date:  1993 Nov-Dec

7.  Action of the antiepileptic drug, valproic acid, on fatty acid oxidation in isolated rat hepatocytes.

Authors:  F X Coudé; G Grimber; A Pelet; Y Benoit
Journal:  Biochem Biophys Res Commun       Date:  1983-09-15       Impact factor: 3.575

8.  Plasma glutathione peroxidase and its relationship to renal proximal tubule function.

Authors:  J C Whitin; D M Tham; S Bhamre; D B Ornt; J D Scandling; B M Tune; O Salvatierra; N Avissar; H J Cohen
Journal:  Mol Genet Metab       Date:  1998-11       Impact factor: 4.797

Review 9.  Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features.

Authors:  B L Clarke; A G Wynne; D M Wilson; L A Fitzpatrick
Journal:  Clin Endocrinol (Oxf)       Date:  1995-10       Impact factor: 3.478

10.  Enzyme cytochemistry combined with electron microscopy, pharmacokinetics, and clinical chemistry for the evaluation of the effects of steady-state valproic acid concentrations on the mouse.

Authors:  R Graf; R Gossrau; H J Merker; R Schwabe; R Stahlmann; H Nau
Journal:  Histochemistry       Date:  1985
View more
  2 in total

1.  Risk factors for sodium valproate-induced renal tubular dysfunction.

Authors:  Satoko Koga; Takahisa Kimata; Sohsaku Yamanouchi; Shoji Tsuji; Ken Yoshimura; Atsushi Araki; Kazunari Kaneko
Journal:  Clin Exp Nephrol       Date:  2017-08-23       Impact factor: 2.801

2.  Vitamin U has a protective effect on valproic acid-induced renal damage due to its anti-oxidant, anti-inflammatory, and anti-fibrotic properties.

Authors:  Selda Gezginci-Oktayoglu; Ismet Burcu Turkyilmaz; Merve Ercin; Refiye Yanardag; Sehnaz Bolkent
Journal:  Protoplasma       Date:  2015-03-24       Impact factor: 3.356

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.